Yes, though the combination patent creates, assuming DCVax is approved, a 2nd, 3rd, fourth etc., level of chess with all the companies that have such classes of drugs. It’s pay to play. The table is set once that patent is approved and any of them can come and play chess not with NWBO but with their other competitors. It creates an opportunity for DCVax to be the tool upon which myriad chess games can be played by big players against each other using the DCVax platform as the playing field.
News 
Market Data 
Discover 
